September 25, 2021

The Psychedelic News Bulletin

AbCellera acquires transmembrane protein producer; Compass gains psychedelic IP portfolio – Endpoints News

6 min read
AbCellera acquires transmembrane protein producer; Compass gains psychedelic IP portfolio  Endpoints News...

Cana­di­an an­ti­body shop Ab­Cellera ac­quired Mass­a­chu­setts biotech Tetra­Ge­net­ics in an all-cash trans­ac­tion. While more spe­cif­ic de­tails were not made pub­licly avail­able, Ab­Cellera did say in a state­ment that the ac­qui­si­tion in­cludes an up­front pay­ment and po­ten­tial mile­stone pay­ments based on tech­ni­cal achieve­ments, suc­cess­ful R&D and com­mer­cial­iza­tion.

Carl Hansen

Found­ed in 2004, Tetra­Ge­net­ics spe­cial­izes in pro­tein pro­duc­tion — specif­i­cal­ly trans­mem­brane pro­teins, which have proven to be dif­fi­cult to pro­duce in the past. Where Tetra­Ge­net­ics comes in­to the equa­tion with Ab­Cellera is that Tetra­Ge­net­ics can make enough trans­mem­brane pro­teins to sup­port an­ti­body dis­cov­ery.

Hav­ing slow­ly built up a net­work of bio­phar­ma clients in re­cent years, Ab­Cellera shot to fame dur­ing the pan­dem­ic as Eli Lil­ly tapped it for Covid-19 an­ti­body part­ner­ship.

“We look for­ward to wel­com­ing the Tetra­Ge­net­ics team and be­lieve that these new ca­pa­bil­i­ties, once in­te­grat­ed in­to Ab­Cellera’s tech­nol­o­gy stack, will em­pow­er the dis­cov­ery of new an­ti­body ther­a­pies across a range of ther­a­peu­tic ar­eas,” said Ab­Cellera CEO Carl Hansen in a state­ment.

Com­pass Path­ways ac­quires IP port­fo­lio of psy­che­del­ic com­pounds

UK biotech Com­pass Path­ways has gained ac­cess to an in­tel­lec­tu­al prop­er­ty port­fo­lio in­clud­ing patent ap­pli­ca­tions cov­er­ing a va­ri­ety of psy­che­delics, em­pathogens and pro­drugs. The IP was de­vel­oped to­geth­er with Matthias Grill, founder and CEO of MiHKAL. Based in Basel, Switzer­land, Grill will be work­ing with Com­pass to de­vel­op new prod­uct can­di­dates.

Grill has been in­volved in psy­che­del­ic chem­istry re­search for over 15 years, and he has held po­si­tions as head of R&D at Ar­bolea, Lipomed and THC Pharm. He has al­so syn­the­sized psy­che­del­ic sub­stances for a num­ber of hu­man re­search stud­ies, in­clud­ing at the Uni­ver­si­ty of Basel and the Na­tion­al In­sti­tute of Men­tal Health in the Czech Re­pub­lic.

“We are de­light­ed to be work­ing with Matthias and MiHKAL GmbH. This agree­ment will strength­en and ex­pand our IP and de­vel­op­ment port­fo­lio with new com­pounds. We plan to move some of these com­pounds in­to clin­i­cal de­vel­op­ment with­in the next two years,” said Com­pass CBO and pres­i­dent Lars Wilde in a state­ment.

Zai Lab re­ceives BTD ap­proval in Chi­na for be­mar­ituzum­ab

Zai Lab re­ceived a break­through des­ig­na­tion to­day from the Cen­ter for Drug Eval­u­a­tion of NM­PA for be­mar­ituzum­ab — as first-line treat­ment for pa­tients with cer­tain types of mu­tat­ed gas­tric and GEJ can­cers in tan­dem with chemo pro­to­col FOL­FOX6 (flu­o­ropy­rim­i­dine, leu­cov­orin, and ox­ali­platin).

Alan San­dler

The des­ig­na­tion is sup­port­ed by re­sults from the Phase II FIGHT study, which eval­u­at­ed be­mar­ituzum­ab plus chemother­a­py ver­sus chemother­a­py alone in pa­tients with FGFR2b over­ex­pres­sion, HER2-neg­a­tive front­line ad­vanced gas­tric or GEJ can­cer.

All three ef­fi­ca­cy end­points in the FIGHT tri­al — PFS, OS and ORR — achieved pre-spec­i­fied sta­tis­ti­cal sig­nif­i­cance in the be­mar­ituzum­ab arm com­pared to the place­bo arm.

“We look for­ward to work­ing with reg­u­la­to­ry au­thor­i­ties in Chi­na as we ad­vance be­mar­ituzum­ab in­to glob­al, reg­is­tra­tional stud­ies,” Zai Lab pres­i­dent and head of glob­al de­vel­op­ment for on­col­o­gy Alan San­dler said in a state­ment.

Zai Lab li­censed Chi­na rights to be­mar­ituzum­ab from Five Prime be­fore Am­gen bought it in a $2 bil­lion deal.

Novo­cure an­nounces col­lab­o­ra­tion with Roche to eval­u­ate tu­mor treat­ing fields in clin­i­cal tri­al

Novo­cure is col­lab­o­rat­ing with Roche in a Phase II clin­i­cal tri­al to test tu­mor treat­ing fields with Roche’s PD-L1 block­er Tecen­triq (ate­zolizum­ab) in metasta­t­ic pan­cre­at­ic duc­tal ade­no­car­ci­no­ma (mP­DAC).

William Doyle

“We are pleased to col­lab­o­rate with Roche, a glob­al leader in on­col­o­gy, to ex­plore the ef­fi­ca­cy of TTFields to­geth­er with ate­zolizum­ab im­munother­a­py in pan­cre­at­ic can­cer,” said Novo­cure ex­ec­u­tive chair­man William Doyle in a state­ment.

The Phase II study will test safe­ty and ef­fi­ca­cy of TTFields to­geth­er with Tecen­triq, gem­c­itabine and nab-pa­cli­tax­el as a first-line treat­ment for mP­DAC. With plans to en­roll ap­prox­i­mate­ly 75 pa­tients in the EU and Unit­ed States, the pri­ma­ry end­point of the study is dis­ease con­trol rate as de­fined by RE­CIST 1.1 guid­ance.

Novo­cure is the study spon­sor and Roche is pro­vid­ing Tecen­triq for the tri­al.

Biotech rais­es $40M to pay CEO and fund R&D, among oth­er things

Penn­syl­va­nia biotech Vir­pax re­vealed the pric­ing of an un­der­writ­ten pub­lic of­fer­ing of 6,670,000 shares of its com­mon stock. List­ed at a pub­lic of­fer­ing price of $6.00 per share, Vir­pax in­tends to raise gross pro­ceeds of just over $40 mil­lion be­fore de­duct­ing un­der­writ­ing dis­counts and of­fer­ing ex­pens­es.

Un­der­writ­ers have been giv­en a 45-day op­tion to pur­chase up to an ad­di­tion­al 1,000,500 shares of com­mon stock to cov­er over-al­lot­ments at the pub­lic of­fer­ing price, mi­nus the un­der­writ­ing dis­count.

Vir­pax in­tends to use the net pro­ceeds from the of­fer­ing to fund R&D for Epo­la­derm, Probudur, En­velta, An­Qlar and oth­er de­vel­op­ment pro­grams, re­pay out­stand­ing promis­so­ry notes and de­ferred com­pen­sa­tion to Vir­pax CEO An­tho­ny Mack, and then the rest of the funds for work­ing cap­i­tal.

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © All rights reserved. | Newsphere by AF themes.